MedWatch

Ambu heir: "We're in it for the long haul, but I would be lying if I said I don't keep track of the share price. I check in daily"

Simon Hesse Hoffmann sits on the powerful family committee overseeing the family's interests in the ownership over the billion-dollar company, Ambu. One of his most important tasks is ensuring the stability and unity of the owner families.

Photo: Privat / PR

They're worth billions but live almost anonymously, far from the prying eyes of public.

In a rare interview, Ambu heir Simon Hesse Hoffmann unveils how the family behind the much discussed medtech Ambu actually manages its ownership.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs